Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study

Abstract Background Venetoclax (VEN) and azacitidine (AZA) are used to treat patients with newly diagnosed acute myeloid leukaemia (AML) who are unfit for intensive chemotherapy and those with relapsed or refractory AML. Understanding the real-world usage patterns and outcomes after VEN-AZA therapy...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jie-Fei Bai, Ting Wang, Jiang-Tao Li, Chun-Li Zhang, Long Qian, Ya-Zi Yang, Xiao-Ya Yun, Jing-Jing Yin, Fei Zhao, Wei-Dong Ding, Bao-Li Xing, Shang-Yong Ning, Lei Pei, Xiao-Dong Xu, Hui Liu, Ru Feng
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2025-06-01
Цуврал:	BMC Cancer
Нөхцлүүд:	Acute myeloid leukemia Hypomethylating agents Venetoclax Relapse Refractory
Онлайн хандалт:	https://doi.org/10.1186/s12885-025-14167-z
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!